SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 11 05 2022
accepted: 06 01 2023
entrez: 9 2 2023
pubmed: 10 2 2023
medline: 11 2 2023
Statut: epublish

Résumé

SARS-CoV-2 continues to pose a threat to human health as new variants emerge and thus a diverse vaccine pipeline is needed. We evaluated SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel

Identifiants

pubmed: 36756130
doi: 10.3389/fimmu.2023.941281
pmc: PMC9900178
doi:

Substances chimiques

Aluminum Hydroxide 5QB0T2IUN0
Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

941281

Informations de copyright

Copyright © 2023 Christensen, Polacek, Sheward, Hanke, McInerney, Murrell, Hartmann, Jensen, Zimmermann, Jungersen, Illigen, Isling, Fernandez-Antunez, Ramirez, Bukh and Pedersen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

EBioMedicine. 2022 Oct;84:104248
pubmed: 36088218
Viruses. 2022 May 16;14(5):
pubmed: 35632800
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2118312119
pubmed: 35561224
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell Host Microbe. 2020 Sep 9;28(3):445-454.e6
pubmed: 32585135
Vaccines (Basel). 2021 May 12;9(5):
pubmed: 34066016
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Science. 2020 Sep 18;369(6510):1505-1509
pubmed: 32703908
Vet Pathol. 2013 May;50(3):534-42
pubmed: 23242804
Microorganisms. 2021 May 12;9(5):
pubmed: 34065996
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell Rep. 2022 Aug 16;40(7):111214
pubmed: 35952673
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
NPJ Vaccines. 2018 Oct 10;3:51
pubmed: 30323958
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
PLoS Pathog. 2020 Dec 4;16(12):e1009089
pubmed: 33275640
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0009721
pubmed: 33903110
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Sci Transl Med. 2020 Aug 5;12(555):
pubmed: 32690628
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
EBioMedicine. 2021 Jan;63:103197
pubmed: 33422991
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
EBioMedicine. 2021 Sep;71:103519
pubmed: 34419923
Lancet. 2022 Jan 29;399(10323):461-472
pubmed: 35065705
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Cell. 2020 Jul 9;182(1):50-58.e8
pubmed: 32516571
Sci Rep. 2021 Apr 22;11(1):8761
pubmed: 33888840
Sci Transl Med. 2021 Aug 11;13(606):
pubmed: 34285130
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Nat Commun. 2020 Sep 4;11(1):4420
pubmed: 32887876
Nat Commun. 2020 Oct 21;11(1):5337
pubmed: 33087721
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
Cell Rep Med. 2021 Nov 16;2(11):100450
pubmed: 34723224
Vaccine. 2014 Jul 31;32(35):4550-4557
pubmed: 24950357
Sci Transl Med. 2011 Jun 1;3(85):85ra48
pubmed: 21632986
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Cell Rep. 2021 Jul 20;36(3):109400
pubmed: 34245672
J Immunol Methods. 2019 Oct;473:112630
pubmed: 31301278
Clin Immunol. 2016 Aug;169:16-27
pubmed: 27236001
PLoS One. 2018 Jun 8;13(6):e0198528
pubmed: 29883460

Auteurs

Dennis Christensen (D)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Charlotta Polacek (C)

Virus Research and Development Laboratory, Department of Microbial Diagnostic and Virology, Statens Serum Institut, Copenhagen, Denmark.

Daniel J Sheward (DJ)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Leo Hanke (L)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Gerald McInerney (G)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Ben Murrell (B)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Katrine Top Hartmann (KT)

Department of Veterinary and Animal Sciences, University of Copenhagen, Copenhagen, Denmark.

Henrik Elvang Jensen (HE)

Department of Veterinary and Animal Sciences, University of Copenhagen, Copenhagen, Denmark.

Julie Zimmermann (J)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Gregers Jungersen (G)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Kristin Engelhart Illigen (KE)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Louise Krag Isling (LK)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Carlota Fernandez-Antunez (C)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Santseharay Ramirez (S)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jens Bukh (J)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Gabriel Kristian Pedersen (GK)

Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH